DDInter1274 DDInter899
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nefazodone {u} (Compound) resembles {v} (Compound) Hydroxyzine
Nefazodone {u} (Compound) resembles {v} (Compound) Trifluoperazine
Nefazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
Nefazodone {u} (Compound) upregulates {v} (Gene) SERPINA3
Nefazodone {u} (Compound) palliates {v} (Disease) endogenous depression
Nefazodone {u} (Compound) downregulates {v} (Gene) ADI1
Nefazodone {u} (Compound) causes {v} (Side Effect) Laryngitis
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Nefazodone (Compound) resembles Hydroxyzine (Compound)
Nefazodone (Compound) resembles Trifluoperazine (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Nefazodone (Compound) binds CYP3A4 (Gene)
Nefazodone (Compound) upregulates SERPINA3 (Gene)
Nefazodone (Compound) palliates endogenous depression (Disease)
Nefazodone (Compound) downregulates ADI1 (Gene)
Nefazodone (Compound) causes Laryngitis (Side Effect)
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Bexarotene